(MedPage Today) — BERLIN — Patients with metastatic hormone-sensitive prostate cancer (mHSPC) lived significantly longer without disease progression with the addition of radioligand therapy to hormonal treatment, a large randomized trial showed…
Source link : https://www.medpagetoday.com/meetingcoverage/esmo/118061
Author :
Publish date : 2025-10-21 15:49:00
Copyright for syndicated content belongs to the linked Source.
